pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ASTRAZENECA · news · pharmadog
← back to ASTRAZENECA
News mentioning ASTRAZENECA
491
stories
16d
Faeth’s phase 2 data power oral combo forward in cancer targeted by ADC heavyweights
fiercebiotech
17d
RevMed’s Rasonque shatters analyst estimates with $198M quarter
biospace
17d
Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca
biospace
17d
AstraZeneca said to offer $10B to acquire Rhythm, analysts whisper of a bidding war
fiercebiotech
18d
First wave of #ASH26 abstracts is here, with data from J&J, Servier and AstraZeneca
endpoints
18d
STAT+: Pharmalittle: We’re reading about CVS plans to split up, FDA inspections in India and China and more
stat
18d
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
biospace
18d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
19d
STAT+: Pharmalittle: We’re reading about a generic HIV prevention shot, Lonza buying U.S. facilities, and more
stat
19d
UniQure gets an FDA decision date; Teva scraps brain drug study
biopharma dive
19d
AbbVie invests £120M in UK, including expanded R&D site
fiercebiotech
20d
STAT+: FDA OKs generic HIV prevention shot, widening access for lower-income countries
stat
20d
STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more
stat
20d
Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
biopharma dive
20d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
23d
AstraZeneca says reorg could mean R&D cuts and trials shifted to emerging markets
endpoints
23d
AstraZeneca employs $1.5B cost savings to reinvest back into growth
biospace
23d
STAT+: Up and down the ladder: The latest comings and goings
stat
23d
STAT+: Pharmalittle: We’re reading about AstraZeneca cost-cutting, Sun Pharma facility problems, and more
stat
23d
AstraZeneca follows GSK with $1.5B annual savings push
endpoints
23d
AstraZeneca cuts early-phase prostate cancer pipeline
fiercebiotech
25d
AstraZeneca’s bruising summer raises the stakes for 2027
endpoints
25d
GSK predicts ‘some limited impact’ to UK roles as restructuring rolls on
fiercebiotech
25d
Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
fiercebiotech
25d
Big Pharma is ready to strike, with J&J most likely to buy: Leerink
biospace
26d
A possible treatment for brain-eating amoebas, found in the sea
stat
26d
From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
fiercebiotech
27d
BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study
biopharma dive
27d
Aspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCs
endpoints
27d
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
biospace
← prev
page 2 of 17
next →